Fox Chase Cancer Center Names Cancer Prevention Pavilion in Honor of Immediate Past President Young
PHILADELPHIA (July 10, 2007) — Fox Chase Cancer Center's board of directors recently voted to rename the Center's Cancer Prevention Pavilion in honor of immediate past president Robert C. Young, MD, of Philadelphia's Chestnut Hill section. The move recognizes Young's many accomplishments during his long tenure as president and CEO, which began in December 1988 and ended June 1.
Opened in January 2000, the Robert C. Young, MD, Pavilion for Cancer Prevention Research houses the first comprehensive program of cancer prevention research, a visionary program that is a highlight of Young's legacy.
"Bob Young's vision of working toward a future free of cancer for our children and grandchildren gave him the commitment and drive to bring cancer prevention research to the forefront," said board chairman William J. Avery. "His nurturing of innovative ideas in cancer prevention while building on Fox Chase's long history of leadership in this field has provided tremendous opportunities."
The Robert C. Young Cancer Prevention Pavilion represents only the second campus building named for an individual and the only one so named during the person's lifetime. The Reimann Building, which includes the first research facilities on the Fox Chase campus, is named for the first scientific director, Stanley P. Reimann, MD.
Young is internationally known for his work in the treatment of lymphoma and ovarian cancer. He became president of Fox Chase in December 1988 after serving as chief of NCI's medicine branch and associate director of the NCI cancer centers and community oncology program. He is a past-president of the American Cancer Society, the American Society of Clinical Oncology (ASCO), and the International Gynecologic Cancer Society.
He received ASCO's Distinguished Service Award for Scientific Leadership in 2004 and was co-recipient of the 2002 Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research for his research in ovarian cancer.
Young chairs the Board of Scientific Advisors of the National Cancer Institute (NCI) and recently completed his appointment to the National Cancer Policy Board at the Institute of Medicine. A fellow of the American College of Physicians, Young is also a member of the prestigious American Society of Clinical Investigation.
Young's successor as Fox Chase president and CEO, , came to Fox Chase from Massachusetts General Hospital and Dana-Farber Cancer Institute. He has appointed Young to the newly created post of chancellor, in which he will continue advocating for Fox Chase Cancer Center at both the national and state levels.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.